SLEDAI-2K: Validated scoring for measuring disease activity in SLE patients.
CNS
Vascular
Musculoskeletal
Renal
Derm
Serosa
Labs
Sys
Select Descriptors
Select the clinical and laboratory descriptors present in the last 10 days to calculate your SLEDAI-2K score.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
Tracking disease activity in systemic lupus erythematosus (SLE) over time
Guiding immunosuppressive therapy decisions in SLE
Clinical trial endpoint for SLE therapeutics
Serial monitoring for flare detection and treatment response
Assessing disease activity at a single visit (last 10 or 30 days)
Patient Population
Contraindications
Not designed for non-lupus systemic autoimmune diseases
Does not assess damage or chronic irreversible organ dysfunction
Cannot distinguish active inflammation from chronic damage in some organ systems
How it Works
Score Components
| Weight | Descriptor | Definition |
|---|---|---|
| 8 | Seizure | Recent onset, exclude metabolic causes |
| 8 | Psychosis | Altered ability to function due to severe disturbance of reality |
| 8 | Organic brain syndrome | Impaired cognition with disorientation or memory deficit |
| 8 | Visual disturbance | Retinal changes, including cytoid bodies or retinal hemorrhages |
| 8 | Cranial nerve disorder | New onset motor or sensory neuropathy |
| 8 | Lupus headache | Severe, persistent headache unresponsive to narcotics |
| 8 | CVA | New cerebrovascular accident, exclude atherosclerosis |
| 8 | Vasculitis | Ulceration, gangrene, tender nodules, or angiographic confirmation |
| 4 | Arthritis | ≥ 2 joints with pain and signs of inflammation |
| 4 | Myositis | Proximal weakness with elevated CPK or EMG changes |
| 4 | Urinary casts | Heme-granular or RBC casts |
| 4 | Hematuria | > 5 RBC/hpf, exclude stone or infection |
| 4 | Proteinuria | > 0.5 g/24h, new onset or recent increase |
| 4 | Pyuria | > 5 WBC/hpf, exclude infection |
| 2 | New rash | New onset or recurrent inflammatory rash |
| 2 | Alopecia | New or recent abnormal hair loss |
| 2 | Mucosal ulcers | New or recent oral or nasal ulcerations |
| 2 | Pleurisy | Pleural rub, effusion, or pleuritic chest pain |
| 2 | Pericarditis | Pericardial rub, effusion, or ECG confirmation |
| 2 | Low complement | CH50, C3, or C4 decreased below lower limit of normal |
| 2 | Increased DNA binding | Anti-dsDNA above normal by Farr or ELISA assay |
| 1 | Fever | > 38 °C, exclude infection |
| 1 | Thrombocytopenia | < 100,000 platelets/mm³ |
| 1 | Leukopenia | < 3,000 WBC/mm³, exclude drug causes |
Scoring Method
Each descriptor present in the preceding 30 days is assigned its weighted score. The total SLEDAI-2K score is the sum of all weighted descriptors present. Scores range from 0 to 105. Items that are improving or resolving are still scored if present.
Clinical Pearls
Clinical Application
SLEDAI-2K is the most widely used lupus disease activity measure. Its weighting system means that a single CNS event (seizure = 8 points) alone can indicate high disease activity, while the absence of high-weighted items does not guarantee quiescent disease. Serial SLEDAI-2K scores are more informative than single measurements. A change of ≥ 4 points is considered clinically meaningful.
Pitfalls to Avoid
Items must be attributed to active lupus, not infection, drug effect, or other causes
Do not score items that are due to damage rather than activity
The 30-day window may miss rapid fluctuations; shorter intervals are appropriate for flares
Proteinuria scoring requires comparison to prior values to distinguish new increase from chronic
Fever and cytopenias have many non-lupus causes; attribute carefully
Next Steps
Score Interpretation Guide
| Score Range | Disease Activity | Clinical Action |
|---|---|---|
| 0 | Inactive | Maintain therapy; monitor every 3–6 months |
| 1 – 5 | Mild | Continue current therapy; consider mild adjustments if trending upward |
| 6 – 10 | Moderate | Consider escalation of immunosuppression; evaluate organ involvement |
| 11 – 19 | High | Escalate therapy; consider corticosteroids + DMARD/biologic |
| ≥ 20 | Very high | Urgent intervention; hospitalisation often required |
Treatment Implications
A SLEDAI-2K score of ≥ 6 typically warrants treatment escalation. The specific intervention depends on the organ systems involved. For renal activity (casts, hematuria, proteinuria), a renal biopsy should be strongly considered. For hematologic activity, the degree and trend of cytopenias guide management. Serologic markers (low complement, increased DNA binding) alone should not drive treatment without clinical correlates.
When to Reassess
Every 1–3 months during active disease or treatment escalation
Every 3–6 months during stable disease
Monthly during renal flare management
Immediately if new symptoms suggest a flare
The Evidence
Key Evidence
SLEDAI-2K was validated against physician global assessment and original SLEDAI with strong concordance
Used as the primary efficacy endpoint in multiple SLE clinical trials (e.g., BLISS trials for belimumab)
Correlates with damage accrual, mortality, and quality of life across diverse SLE cohorts
The 30-day window in SLEDAI-2K improved usability without sacrificing validity compared to the 10-day SLEDAI
Primary Reference
Systemic lupus erythematosus disease activity index 2000.
Gladman DD et al. • Journal of Rheumatology. 2002;29(2):288-91
Derivation of the SLEDAI. A disease activity index for lupus patients.
Bombardier C et al. • Arthritis and Rheumatism. 1992;35(6):630-40
Origins & History
Development
The original SLEDAI was developed in 1992 by the Toronto Lupus Clinic using a Delphi consensus process with 15 international lupus experts. The SLEDAI-2K modification in 2002 allowed persistent active disease (rash, alopecia, mucosal ulcers, proteinuria) to be scored continuously rather than only if new or recurrent, improving sensitivity to ongoing disease activity. It remains the most commonly used lupus activity measure in both clinical trials and routine practice.
Last Comprehensive Review: 2026-07-17